[Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura].

Wang L, Guo CS, Hou M, Li LZ, Zhang CQ, Chen F, Qin P, Peng J, He WD, Chu XX

Zhonghua nei ke za zhi1 Apr 2007Cited by 1 (Europe PMC)

PMID17637261PepBankPUB-17637261

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with chronic idiopathic thrombocytopenic purpura, adding thymosin alpha1 to high-dose dexamethasone raised the complete response rate versus dexamethasone alone.
In plain wordsIn patients with chronic ITP, adding thymosin alpha‑1 to dexamethasone gave more complete responses than dexamethasone alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseComplete response rate
Study
n = 66
Comparator
HD-Dex alone
Outcome group
Overall treatment effect · Immune and inflammation
Studied dose
1.6 mg thrice weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Complete response rate
76.9%
HD-Dex plus Talpha(1)
Complete response rate
44.4%
HD-Dex
Source sentences
Summary
(1) Twelve patients (44.4%) in HD-Dex treatment group and thirty patients (76.9%) in HD-Dex plus Talpha(1) treatment group achieved complete response respectively (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
Report a problemFND-1763726101
02HumanNon-randomized trialEfficacy outcome
In patients with chronic idiopathic thrombocytopenic purpura, adding thymosin alpha1 to high-dose dexamethasone raised the sustained response rate at 6 months versus dexamethasone alone.
In plain wordsIn patients with chronic ITP, adding thymosin alpha‑1 to dexamethasone gave more lasting responses at 6 months than dexamethasone alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseSustained response rate at 6 months
Study
n = 65
Comparator
HD-Dex alone
Outcome group
Overall treatment effect · Immune and inflammation
Studied dose
1.6 mg thrice weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Sustained response rate
61.5%
HD-Dex plus Talpha(1)
Sustained response rate
34.6%
HD-Dex
Source sentences
Summary
After a follow-up period of 6 months, HD-Dex plus Talpha(1) treatment group showed a significantly greater rate of sustained response (24/39, 61.5%) and a lower replacing rate (15/39, 38.5%) than HD-Dex treatment group (9/26, 34.6%; 17/26, 65.4%) (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
Report a problemFND-1763726102
03HumanNon-randomized trialEfficacy outcome
In patients with chronic idiopathic thrombocytopenic purpura, adding thymosin alpha1 to high-dose dexamethasone lowered the replacing rate at 6 months versus dexamethasone alone.
In plain wordsIn patients with chronic ITP, adding thymosin alpha‑1 to dexamethasone gave a lower replacing rate at 6 months than dexamethasone alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseReplacing rate at 6 months
Study
n = 65
Comparator
HD-Dex alone
Outcome group
Overall treatment effect · Immune and inflammation
Studied dose
1.6 mg thrice weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Replacing rate
38.5%
HD-Dex plus Talpha(1)
Replacing rate
65.4%
HD-Dex
Source sentences
Summary
After a follow-up period of 6 months, HD-Dex plus Talpha(1) treatment group showed a significantly greater rate of sustained response (24/39, 61.5%) and a lower replacing rate (15/39, 38.5%) than HD-Dex treatment group (9/26, 34.6%; 17/26, 65.4%) (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
Report a problemFND-1763726103

Studies that did not test the peptide alone11

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

04HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialPharmacokinetics
In patients with chronic idiopathic thrombocytopenic purpura given dexamethasone plus thymosin alpha1, plasma Talpha(1) levels decreased after treatment.
In plain wordsIn patients with chronic ITP given dexamethasone plus thymosin alpha‑1, blood thymosin alpha‑1 levels were lower after treatment.
Peptide
Thymosin alpha-1
Outcome
DecreasePlasma Talpha(1) level after treatment
Study
n = 39
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
(2) After treatment, a remarkable decrease of Talpha(1) levels was seen HD-Dex plus Talpha(1) treatment group [(2.43 +/- 1.47), (1.83 +/- 1.22)] microg/L (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726104
05HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP in the dexamethasone plus thymosin alpha1 group, plasma IFN-gamma was higher than in controls.
In plain wordsIn patients with chronic ITP given dexamethasone plus thymosin alpha‑1, blood IFN-gamma was higher than in controls.
Peptide
Thymosin alpha-1
Outcome
IncreasePlasma IFN-gamma versus controls
Study
n = 39
Comparator
Controls
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
(3) In HD-Dex plus Talpha(1) treatment group, the plasma levels of both IFNgamma and IL-2 were significantly higher [(22.71 +/- 7.98), (28.42 +/- 11.27)] ng/L than those in controls [(10.23 +/- 3.97), (8.73 +/- 8.22)] ng/L (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726105
06HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP in the dexamethasone plus thymosin alpha1 group, plasma IL-2 was higher than in controls.
In plain wordsIn patients with chronic ITP given dexamethasone plus thymosin alpha‑1, blood IL-2 was higher than in controls.
Peptide
Thymosin alpha-1
Outcome
IncreasePlasma IL-2 versus controls
Study
n = 39
Comparator
Controls
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
(3) In HD-Dex plus Talpha(1) treatment group, the plasma levels of both IFNgamma and IL-2 were significantly higher [(22.71 +/- 7.98), (28.42 +/- 11.27)] ng/L than those in controls [(10.23 +/- 3.97), (8.73 +/- 8.22)] ng/L (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726106
07HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP in the dexamethasone plus thymosin alpha1 group, plasma IL-4 was lower than in controls.
In plain wordsIn patients with chronic ITP given dexamethasone plus thymosin alpha‑1, blood IL-4 was lower than in controls.
Peptide
Thymosin alpha-1
Outcome
DecreasePlasma IL-4 versus controls
Study
n = 39
Comparator
Controls
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The levels of both IL-4 and IL-10 were significantly lower [(5.93 +/- 3.85), (3.24 +/- 1.36)] ng/L after treatment as compared with those in the controls [(14.39 +/- 8.03), (8.67 +/- 3.04)] ng/L (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726107
08HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP in the dexamethasone plus thymosin alpha1 group, plasma IL-10 was lower than in controls.
In plain wordsIn patients with chronic ITP given dexamethasone plus thymosin alpha‑1, blood IL-10 was lower than in controls.
Peptide
Thymosin alpha-1
Outcome
DecreasePlasma IL-10 versus controls
Study
n = 39
Comparator
Controls
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The levels of both IL-4 and IL-10 were significantly lower [(5.93 +/- 3.85), (3.24 +/- 1.36)] ng/L after treatment as compared with those in the controls [(14.39 +/- 8.03), (8.67 +/- 3.04)] ng/L (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726108
09HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma IFN-gamma decreased after treatment with dexamethasone plus thymosin alpha1.
In plain wordsIn patients with chronic ITP, blood IFN-gamma fell after treatment with dexamethasone plus thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
DecreasePlasma IFN-gamma after treatment
Study
n = 39
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, IFNgamma and IL-2 decreased [(11.57 +/- 4.33), (14.56 +/- 10.76)] ng/L (P < 0.01) and IL-4 and IL-10 increased greatly [(9.87 +/- 4.82), (7.90 +/- 2.71)] ng/L (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726109
10HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma IL-2 decreased after treatment with dexamethasone plus thymosin alpha1.
In plain wordsIn patients with chronic ITP, blood IL-2 fell after treatment with dexamethasone plus thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
DecreasePlasma IL-2 after treatment
Study
n = 39
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, IFNgamma and IL-2 decreased [(11.57 +/- 4.33), (14.56 +/- 10.76)] ng/L (P < 0.01) and IL-4 and IL-10 increased greatly [(9.87 +/- 4.82), (7.90 +/- 2.71)] ng/L (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726110
11HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma IL-4 increased after treatment with dexamethasone plus thymosin alpha1.
In plain wordsIn patients with chronic ITP, blood IL-4 rose after treatment with dexamethasone plus thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
IncreasePlasma IL-4 after treatment
Study
n = 39
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, IFNgamma and IL-2 decreased [(11.57 +/- 4.33), (14.56 +/- 10.76)] ng/L (P < 0.01) and IL-4 and IL-10 increased greatly [(9.87 +/- 4.82), (7.90 +/- 2.71)] ng/L (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726111
12HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma IL-10 increased after treatment with dexamethasone plus thymosin alpha1.
In plain wordsIn patients with chronic ITP, blood IL-10 rose after treatment with dexamethasone plus thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
IncreasePlasma IL-10 after treatment
Study
n = 39
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
After treatment, IFNgamma and IL-2 decreased [(11.57 +/- 4.33), (14.56 +/- 10.76)] ng/L (P < 0.01) and IL-4 and IL-10 increased greatly [(9.87 +/- 4.82), (7.90 +/- 2.71)] ng/L (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726112
13HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma TGF-beta(1) increased after treatment with dexamethasone plus thymosin alpha1.
In plain wordsIn patients with chronic ITP, blood TGF-beta(1) rose after treatment with dexamethasone plus thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
IncreasePlasma TGF-beta(1) after treatment
Study
n = 39
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
(4) TGF-beta(1) in HD-Dex plus Talpha(1) treatment group significantly increased from [(1.31 +/- 0.71), (4.19 +/- 1.80)] microg/L after treatment (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726113
14HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialMechanism
In patients with chronic ITP, plasma Talpha(1) correlated positively with TGF-beta(1).
In plain wordsIn patients with chronic ITP, blood thymosin alpha‑1 levels were linked to higher TGF-beta(1) levels.
Peptide
Thymosin alpha-1
Outcome
Not applicableCorrelation of Talpha(1) with TGF-beta(1)
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Measurements
r
0.6028
Talpha(1) versus TGF-beta(1)
Source sentences
Summary
(5) There was a significantly positive correlation between Talpha(1) and TGF-beta(1) (r = 0.6028, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
(1) Out of sixty-six newly diagnosed patients with chronic idiopathic thrombocytopenic purpura, 27 patients received oral HD-Dex at single daily doses of 40 mg for 4 consecutive days, 39 patients received HD-Dex plus Talpha(1) 1.6 mg subcutaneously thrice weekly for 4 weeks.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1763726114

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.